Zymeworks (ZYME) The Citizens Life Sciences Conference 2026 summary

Strategic overview and business model

• Focus on developing assets to key inflection points, then partnering for upfront payments and long-term royalties.

• Maintains a royalty aggregation model, leveraging stable income from out-licensed assets to fund internal pipeline and potential acquisitions.

• Recently secured a $250 million royalty note, boosting financial flexibility for further asset acquisition and development.

• Current cash position exceeds $500 million, with additional milestone payments expected from regulatory approvals.

• No plans for direct commercialization; strategy centers on value creation through partnerships and royalty streams.

Pipeline highlights and clinical progress

• Zanidatamab, a bispecific HER2 antibody, has shown transformative data in GEA and BTC, with regulatory filings underway and potential US approval expected in the second half of the year.

• Breast cancer trials for zanidatamab are ongoing, with recruitment expected to complete by year-end and data readout anticipated by late 2027 or early 2028.

• Folate receptor alpha ADC demonstrates a wide therapeutic index, promising early efficacy, and a favorable safety profile; additional data expected this year.

• Pasritamig, a T-cell engager targeting KLK2, is advancing into three pivotal studies with J&J, showing manageable safety and strong efficacy signals.

• IND filings for new assets, including a tri-specific T-cell engager (ZW209) and an autoimmune molecule (1528), are planned for 2026.

Financial outlook and upcoming milestones

• Over $500 million in cash and royalty notes available for strategic deployment.

• Anticipates $440 million in regulatory milestone royalties for zanidatamab, plus $90 million for a third indication.

• Key milestones for 2024 include zanidatamab approval filings, breast cancer trial progress, phase 3 initiation for pasritamig, and new data from the folate receptor alpha ADC.

• Plans to showcase GPC3 ADC data by year-end or early next year.

• Ongoing execution of royalty aggregation strategy, including potential acquisitions of royalty-generating companies and assets.